Biotech Acquisition Company (BIOT) financial statements (2022 and earlier)

Company profile

Business Address 545 WEST 25TH STREET
NEW YORK, NY 10001
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments91 
Cash and cash equivalents91 
Prepaid expense208 
Deferred costs 90
Total current assets:29990
Noncurrent Assets
Long-term investments and receivables230,021 
Long-term investments230,021 
Total noncurrent assets:230,021 
TOTAL ASSETS:230,32190
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:313 
Other undisclosed accounts payable and accrued liabilities313 
Due to related parties170
Total current liabilities:31470
Noncurrent Liabilities
Liabilities, other than long-term debt8,650 
Deferred compensation liability, classified8,650 
Other undisclosed noncurrent liabilities18,505 
Total noncurrent liabilities:27,155 
Total liabilities:27,46970
Temporary equity, carrying amount230,021 
Stockholders' equity
Stockholders' equity attributable to parent, including:(27,170)20
Common stock1 
Additional paid in capital 24
Accumulated deficit(27,170)(5)
Other undisclosed stockholders' equity attributable to parent 1
Total stockholders' equity:(27,170)20
TOTAL LIABILITIES AND EQUITY:230,32190

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Operating expenses(1,570) 
Operating loss:(1,570) 
Nonoperating income
(Investment Income, Nonoperating)
21 
Loss before gain (loss) on sale of properties:(1,549) 
Other undisclosed net loss(5,316) 
Net loss available to common stockholders, diluted:(6,865) 

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(6,865) 
Comprehensive loss, net of tax, attributable to parent:(6,865) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: